Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • OxyContin maker Purdue...

    OxyContin maker Purdue Pharma seeks to halt opioid lawsuits

    Farhat NasimWritten by Farhat Nasim Published On 2019-10-12T09:00:48+05:30  |  Updated On 12 Oct 2019 9:00 AM IST
    OxyContin maker Purdue Pharma seeks to halt opioid lawsuits

    New Delhi: OxyContin maker Purdue Pharma LP will ask a U.S. Bankruptcy Judge on Friday to pause litigation against the company and its owners over the objections of U.S. states that allege the company is trying to protect the controlling Sackler family.


    Purdue’s request promises to be one of the most contentious of the company’s Chapter 11 bankruptcy case, which was filed in September to try to implement a settlement proposal it values at more than $10 billion.


    Privately-held Purdue said last month it needed to pause more than 2,600 lawsuits so the company can reduce legal costs and try to win over more plaintiffs to its proposed deal.


    The lawsuits accuse Purdue and the Sacklers of fueling a public health crisis by aggressively marketing opioids while downplaying their overdose risks, contributing to some 400,000 deaths from 1999 to 2017, according to U.S. statistics.


    The company said it has the support of a majority of the local governments that brought the bulk of the lawsuits, although at least 24 states oppose the deal.


    Also Read: Purdue Pharma billion-dollar OxyContin settlement would rank among largest in pharma history


    Massachusetts Attorney General Maura Healey, a settlement opponent, has accused Purdue of protecting the billionaire Sacklers.


    The family has not filed for bankruptcy protection, which generally automatically pauses litigation but also imposes obligations to open financial records. The family has pledged to contribute at least $3 billion to the settlement and will relinquish ownership of Purdue to the plaintiffs.


    States opposed to the settlement disclosed in a court filing last week that Purdue steered about $12 billion in profits to the Sacklers.


    At a Thursday court hearing, a lawyer for Purdue challenged that characterization and said it covered a period dating back to 1995, and was disclosed to plaintiffs a year ago. “The $12 billion figure is in fact not new at all,” said Marshall Huebner, a Davis Polk & Wardwell lawyer who represents Purdue.


    Among other things, Purdue will have to convince U.S. Bankruptcy Judge Robert Drain in White Plains, New York, that pausing litigation is in the public interest.


    Holdout states said their cases are aimed in part at uncovering the extent of the company’s misconduct.


    “This court should not strip the states of their core function to enforce their own regulatory laws in their own courts and administrative bodies,” said a filing last week by the states opposed to the deal.


    Also Read: OxyContin maker Purdue Pharma agrees to provide proprietary research, other data
    Judge Robert DrainMarshall HuebnerNew Yorkopioid lawsuitsOxyContinPurdue PharmaSackler familyUS Bankruptcy
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok